Our Approach
Oleolive was founded by scientists with a desire to move “technology under rocks” forward from traditionally overlooked research institutions. We do this by pairing our team of deep subject matter experts with expert institutional researchers to put therapeutics and medical technologies on a path toward commercialization.
Target Selection
We identify novel and previously dismissed targets that play a role in disease progression for which there are very few therapeutic options. Our targets play a role in diseases of oncology, metabolism, neurology, and longevity. We specialize in discovering these small molecules from novel screening options and through university partnerships.
Early Stage De-Risking
Upon discovery of new drug candidates, we de-risk the development at an early stage by partnering with relevant NIH agencies such as NCI, NHLBI, and NIA to get support for development leading up to the clinic. This approach allows us to be more promiscuous with our “shots on goal”. We have been successful with this approach multiple times.
Collaborative Expertise
New drug candidates are codeveloped through the preclinical stage with collaborators that are experts in the field (generally the inventor). This approach takes advantage of tacit knowledge that would otherwise be lost or hard to replicate internally, it also reduces cost and time to meaningful results.
